SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-023188
Filing Date
2024-03-18
Accepted
2024-03-18 06:30:40
Documents
13
Period of Report
2024-03-15
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0201947-8k_virpaxphrm.htm   iXBRL 8-K 28078
  Complete submission text file 0001213900-24-023188.txt   203472

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE vrpx-20240315.xsd EX-101.SCH 3027
3 XBRL LABEL FILE vrpx-20240315_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE vrpx-20240315_pre.xml EX-101.PRE 22367
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0201947-8k_virpaxphrm_htm.xml XML 3737
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-4597
Virpax Pharmaceuticals, Inc. (Filer) CIK: 0001708331 (see all company filings)

IRS No.: 821510982 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40064 | Film No.: 24756870
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)